Dual inhibition of interleukin-1β and interleukin-18: a new treatment option for sepsis?
1 Infectious Disease Service Alpert Medical School of Brown University Pawtucket, Rhode Island and Memorial Hospital of Rhode Island Pawtucket, Rhode Island.
Steven M
SM
Opal
D000818:Animals; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D001323:Autoantibodies / Q000627:therapeutic use*; D053590:Interleukin 1 Receptor Antagonist Protein / Q000627:therapeutic use*; D020382:Interleukin-18 / Q000172:deficiency*; D053583:Interleukin-1beta / Q000172:deficiency*; D012772:Shock, Septic / Q000517:prevention & control*
D000893:Anti-Inflammatory Agents; D001323:Autoantibodies; D053590:Interleukin 1 Receptor Antagonist Protein; D020382:Interleukin-18; D053583:Interleukin-1beta